PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (MX2011006108) COMPOSICIONES DE INHIBIDORES DE LOS RECEPTORES TIROSINA QUINASA.

Office : Mexico
Application Number: 2011006108 Application Date: 08.06.2011
Publication Number: 2011006108 Publication Date: 18.11.2011
Publication Kind : A
IPC:
C07D 487/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
CPC:
A61K 31/404
A61K 31/4355
A61K 31/4545
A61K 31/4709
A61K 31/495
A61K 31/496
A61K 31/498
A61K 31/4985
A61K 31/519
A61K 31/5377
A61K 31/538
A61K 31/5383
A61K 31/5415
A61K 31/542
A61K 31/55
A61K 31/551
A61K 31/5513
A61K 31/554
A61K 45/06
C07D 215/20
C07D 215/227
C07D 221/12
C07D 221/16
C07D 223/14
C07D 223/16
C07D 241/44
C07D 265/36
C07D 279/16
C07D 281/10
C07D 295/13
C07D 403/12
C07D 413/12
C07D 417/12
C07D 471/04
C07D 487/04
C07D 491/048
C07D 495/04
C07D 498/04
C07D 513/04
A61K 31/497
C07D 221/06
C07D 223/32
C07D 261/20
C07D 307/77
C07D 403/14
C07D 407/12
C07D 413/10
C07D 491/04
C07D 493/06
C07D 498/06
C07D 207/09
Applicants: VM PHARMA LLC.*VM PHARMA LLC.*
Inventors: JAY JIEQUIANG WU
LING WANG
Priority Data: 61/120,827 08.12.2008 US
Title: (ES) COMPOSICIONES DE INHIBIDORES DE LOS RECEPTORES TIROSINA QUINASA.
Abstract:
(EN) The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF recptor TrkA.
Also published as:
EP2376495JP2012511054US20110301133CN102292338RU2011128013CA2746220
JP2014218524KR1020110114565RU0002586212BRPI0922224JP2016180005NZ593937
AU2009333537CN106336400AU2016200153AU2017248456JP2018002741IN5183/DELNP/2011
WO/2010/077680